IPSCO Tubulars IPSC 深 沪
已收盘 10-24 16:00:00 美东时间
0.5773
-0.013
-2.15%
华盛通- 最 高0.60
- 今 开0.595
- 成交量 88.79万股
- 最 低 0.5713
- 昨 收 0.59
- 总市值 4987.24万
- 52周最高 1.83
- 市盈率 静 --
- 换手率 1.03%
- 52周最低 0.3418
- 委 比 -83.18%
- 总股本 8638.91万
- 历史最高 32.899
- 量 比 0.92
- 振 幅 4.86%
- 历史最低 0.3418
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Century Therapeutics announced that its Chief Scientific Officer, Chad Cowan, Ph.D., will present at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The presentation will be live-streamed on Century’s website and available for replay for 30 days. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancer using its Allo-Evasion™ technology. For more inform...
10-14 20:01
Analysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Century Therapeutics (IPSC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-08 16:20
CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived
08-28 21:07
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics' CEO Brent Pfeiffenberger will present at the H.C. Wainwright Global Investment Conference on September 9-10, 2025, in New York. An on-demand webcast of the presentation will be available on September 5, 2025, on the company’s website. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancers, focusing on off-the-shelf therapies to expand patient access.
08-22 12:00
Shineco Launches Blockchain-Driven Cell Technology Division to Speed Global Stem Cell Product Distribution
Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business
08-13 18:33
Century Therapeutics Announces Major Workforce Reduction
An announcement from Century Therapeutics ( ($IPSC) ) is now available. On July...
07-08 04:29
百诚医药：6月30日接受机构调研，财通证券、方正富邦基金等多家机构参与
证券之星消息，2025年7月4日百诚医药（301096）发布公告称公司于2025年6月30日接受机构调研，财通证券、方正富邦基金、德邦基金、宝盈基金、运舟资本、国联基金、惠通基金、青骊投资、国寿安保基金、招商基金、弘尚资产、光大保德信、上海开思私募基金、中金公司、摩根基金参与。
07-04 19:01
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
Century Therapeutics to Present Two Abstracts at EULAR 2025 Congress The company will highlight data on its iPSC-derived cell therapy pipeline for autoimmune diseases and cancer. Abstracts include CNTY-101, a CD19-targeting CAR-NK product, and generation of CAR-NK, γδ CAR-T, and αβ CAR-T cells. Presentations by Hongxia Zhang, Ph.D. and Jonathan Kurtz, Ph.D. will occur on June 12. Additional materials will be available on the company’s website p...
05-28 20:01
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
